CAPR Bathi resik saben saham sajrone 12 wulan pungkasan capricor.com

Chart volatility is driven by fierce competition in the cell therapy sector and the risks associated with genetic innovations. The financial foundation relies on the closed-loop cycle of the Capricor Therapeutics (CAPR) CAP-1002 platform and the modernization of plants to increase drug synthesis. The annual net income per share trend demonstrates current dynamics, where the value of -2.63 reflects the balance of the asset yield metric.

CAPR Bathi saben saham sajroning taun lumaku Capricor Therapeutics (04.07.2022 - 14.11.2026)

Capricor Therapeutics Inc. - rincian analitis lan metrik utama (CAPR)

- rega saham lan target rega konsensus:

Rega saham Capricor|CAPR - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar Capricor Therapeutics, Inc.|CAPR - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Capricor Therapeutics|CAPR - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku capricor.com|CAPR - Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas Capricor Therapeutics|CAPR - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Capricor|CAPR - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Capricor Therapeutics, Inc.|CAPR - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Capricor Therapeutics|Rasio cepet capricor.com

- data bathi lan kelipatan valuasi:

CAPR - Penghasilan resik|Proyeksi bathi mangsa ngarep Capricor Therapeutics|CAPR - Pangali P/E|Rega marang bathi mangsa ngarep Capricor|CAPR - Rasio kapitalisasi marang bathi lan wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Capricor Therapeutics, Inc.|CAPR - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Capricor Therapeutics|CAPR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan capricor.com|CAPR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Capricor Therapeutics

- rincian pendapatan lan dodolan emiten:

CAPR - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan Capricor|CAPR - Rasio kapitalisasi pasar marang pendapatan|Multiplikator forward rega marang pendapatan Capricor Therapeutics, Inc.

Analisis dhasar perusahaan:capricor.com (CAPR)

Capricor Therapeutics (CAPR) investments in the development of cell technologies to combat Duchenne muscular dystrophy define its profit profile, where R&D expenses directly impact the bottom line. Analyzing annual net income per share allows for an assessment of the business's real equity yield, adjusted for issuance volume, which helps investors identify the company's fundamental stability through the price action on this chart.

Analisis perusahaan pesaing